Sodium phenylbutyrate - GMP-Orphan

Drug Profile

Sodium phenylbutyrate - GMP-Orphan

Alternative Names: Satisma

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GMP-Orphan SAS
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity No

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 28 May 2018 No recent reports of development identified for clinical-Phase-Unknown development in Spinal-muscular-atrophy in European Union
  • 28 May 2018 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy(In adolescents, In children, In infants) in France
  • 07 Nov 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top